Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GMTX NASDAQ:ITCI NASDAQ:MOR NASDAQ:MYOK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMTXGemini Therapeutics$57.34+1.9%$50.50$1.16▼$14.10$2.48B-0.12189,291 shs422,820 shsITCIIntra-Cellular Therapies$131.87$131.87$70.90▼$131.98$14.05B0.691.55 million shsN/AMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/AMYOKMyoKardia$224.91$224.61$42.65▼$225.00$11.99B1.84752,969 shsN/ABeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMTXGemini Therapeutics-2.55%+6.23%+4.77%+37.24%+14.30%ITCIIntra-Cellular Therapies0.00%0.00%0.00%0.00%+67.84%MORMorphoSys0.00%0.00%0.00%0.00%+3.04%MYOKMyoKardia0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGMTXGemini TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AITCIIntra-Cellular Therapies0.9207 of 5 stars1.10.00.04.51.31.70.6MORMorphoSysN/AN/AN/AN/AN/AN/AN/AN/AMYOKMyoKardiaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGMTXGemini Therapeutics 0.00N/AN/AN/AITCIIntra-Cellular Therapies 2.17Hold$109.70-16.81% DownsideMORMorphoSys 0.00N/AN/AN/AMYOKMyoKardia 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/AITCIIntra-Cellular Therapies$680.50M20.64N/AN/A$6.15 per share21.44MORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17MYOKMyoKardia$33.56M357.36N/AN/A$8.79 per share25.59Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/AITCIIntra-Cellular Therapies-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%N/AMORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/AMYOKMyoKardia-$276.21M-$4.38N/AN/AN/AN/A-47.99%-42.42%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGMTXGemini TherapeuticsN/AN/AN/AN/AN/AITCIIntra-Cellular TherapiesN/AN/AN/AN/AN/AMORMorphoSysN/AN/AN/AN/AN/AMYOKMyoKardiaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGMTXGemini TherapeuticsN/A71.4971.49ITCIIntra-Cellular TherapiesN/A7.667.51MORMorphoSys4.981.381.38MYOKMyoKardiaN/A21.0321.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGMTXGemini Therapeutics75.42%ITCIIntra-Cellular Therapies92.33%MORMorphoSys18.38%MYOKMyoKardiaN/AInsider OwnershipCompanyInsider OwnershipGMTXGemini Therapeutics12.90%ITCIIntra-Cellular Therapies2.60%MORMorphoSys0.05%MYOKMyoKardia4.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionableITCIIntra-Cellular Therapies560106.52 million103.56 millionOptionableMORMorphoSys730150.62 million150.55 millionNot OptionableMYOKMyoKardia31853.32 millionN/AOptionableMYOK, ITCI, MOR, and GMTX HeadlinesRecent News About These CompaniesFulcrum Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:FULC | BenzingaMarch 27, 2025 | benzinga.comAt $300M Kardigan startup, former MyoKardia team unveils its first drug, and it comes from IonisMarch 7, 2025 | endpts.comEBristol Myers' MyoKardia unit ends work with Fulcrum; ALX discloses layoffsMarch 6, 2025 | endpts.comEBMS builds case for mavacamten label ahead of FDA decisionFebruary 14, 2025 | pharmaphorum.comPCardiac drug developer co-founded by Feinberg's genetic medicine director raises $300MFebruary 3, 2025 | chicagobusiness.comCKardigan raises $300m for cardio work, and other financingsJanuary 17, 2025 | pharmaphorum.comPKardigan launches with cozy $300M series A and collection of late-stage cardio assetsJanuary 10, 2025 | fiercebiotech.comFMyoKardia Alumni Launch Kardigan with $300M to Tackle Heart DiseaseJanuary 10, 2025 | biospace.comBPalace Hotel buffetDecember 28, 2024 | bwhotelier.businessworld.inBBK8 slotDecember 28, 2024 | bwdisrupt.businessworld.inBLook out BMS, Cytokinetics has its eye on mavacamten's turfDecember 6, 2024 | pharmaphorum.comPThryv Therapeutics Announces the Appointment of Esteemed Executive Leader Amy Sehnert, MD, as Chief Medical OfficerNovember 20, 2024 | djournal.comDNew research shows relationship between heart shape and risk of cardiovascular diseaseNovember 14, 2024 | eurekalert.orgEFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024November 13, 2024 | markets.businessinsider.comBiotech investors, including Third Rock, pump $100M into a startup’s genetic medicine for ALSNovember 13, 2024 | biopharmadive.comBBristol's New Schizophrenia Drug Cobenfy Helps Support Its Wide MoatNovember 12, 2024 | morningstar.comMHealthEx Raises $14M led by General Catalyst to Empower Patients and Health Systems to do more with Health DataOctober 21, 2024 | markets.businessinsider.comNew Research Reveals That “Weekend Warrior” Workouts Can Reduce Your Risk of 200+ DiseasesOctober 13, 2024 | scitechdaily.comSMavacamten Shows Promise in Heart Failure With Normal to Supranormal EFOctober 1, 2024 | msn.comBristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)September 27, 2024 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesD-Wave Is Rising Again Despite Dilution—What’s the Deal?By Nathan Reiff | July 7, 2025View D-Wave Is Rising Again Despite Dilution—What’s the Deal?More Than a Monetary Metal: Silver's Case for OutperformanceBy Jeffrey Neal Johnson | June 22, 2025View More Than a Monetary Metal: Silver's Case for Outperformance3 Stocks Hitting All-Time Highs With More Room to RunBy Dan Schmidt | June 27, 2025View 3 Stocks Hitting All-Time Highs With More Room to RunDon’t Miss Out: 3 Blue-Chips Set to Pop This Earnings SeasonBy Chris Markoch | July 8, 2025View Don’t Miss Out: 3 Blue-Chips Set to Pop This Earnings SeasonBig Bank Buybacks: Morgan Stanley, Citi, & Wells Fargo LeadBy Gabriel Osorio-Mazilli | July 3, 2025View Big Bank Buybacks: Morgan Stanley, Citi, & Wells Fargo LeadMYOK, ITCI, MOR, and GMTX Company DescriptionsGemini Therapeutics NASDAQ:GMTX$57.34 +1.07 (+1.90%) As of 07/16/2025Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.Intra-Cellular Therapies NASDAQ:ITCIIntra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.MorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 07/16/2025MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.MyoKardia NASDAQ:MYOKMyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is Mavacamten, an orally administered allosteric modulator of cardiac myosin, which is in Phase III clinical trial for the treatment of hypertrophic cardiomyopathy (HCM). The company also develops Danicamtiv, an orally administered small molecule, which completed Phase I and Phase IIa clinical trials on patients with dilated cardiomyopathy. Its preclinical programs include MYK-224, a small molecule program for the treatment of HCM targeting hypercontractility and impaired relaxation; ACT-1 for the treatment of diastolic dysfunction; and LUS-1 for the treatment of diastolic dysfunction. Myokardia, Inc. was founded in 2012 and is headquartered in Brisbane, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now Citigroup Earnings Could Signal What’s Next for Markets This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
